We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+26.22%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.23B
AUM Growth
+$240M
Cap. Flow
+$116M
Cap. Flow %
9.38%
Top 10 Hldgs %
61.25%
Holding
137
New
51
Increased
28
Reduced
20
Closed
23

Top Buys

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$70.5M
2
CELG
Celgene Corp
CELG
+$37.6M
3
RPRX
Repros Therapeutics Inc.
RPRX
+$27.9M
4
TSRO
TESARO, Inc.
TSRO
+$21.7M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$19.9M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$106M
2
BIIB icon
Biogen
BIIB
+$49.8M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$31.3M
4
STML
Stemline Therapeutics, Inc.
STML
+$16.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 76.94%
2 Financials 0.01%
3 Consumer Staples 0.01%
4 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYAX
26
DELISTED
DYAX CORPORATION
DYAX
$11.6M 0.94%
1,692,912
-29,590
-2% -$134K
CTIC
27
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$11.3M 0.92%
+699,467
New +$8.1M
ANAC
28
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$10.3M 0.84%
973,868
+391,033
+67% +$3.42M
IWM icon
29
PUT
iShares Russell 2000 ETF
IWM
$79.1B
$10.3M 0.84%
+96,500
New +$9.98M
AMGN icon
30
Amgen
AMGN
$209B
$10.3M 0.83%
+91,675
New +$9.94M
CHTP
31
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
$10.2M 0.83%
3,418,365
-1,240,315
-27% -$3.56M
SGMO
32
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$10.1M 0.82%
+965,000
New +$9.58M
WBA
33
DELISTED
Walgreens Boots Alliance
WBA
$10.1M 0.82%
+187,870
New +$9.44M
NPSP
34
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$9.73M 0.79%
305,762
-256,638
-46% -$5.89M
VNDA icon
35
Vanda Pharmaceuticals
VNDA
$304M
$9.51M 0.77%
+868,500
New +$9.28M
WCG
36
DELISTED
Wellcare Health Plans, Inc.
WCG
$9.21M 0.75%
132,081
+131,696
+34,207% +$8.43M
IONS icon
37
Ionis Pharmaceuticals
IONS
$8.93B
$7.24M 0.59%
+192,800
New +$5.76M
ECYT
38
DELISTED
Endocyte, Inc. Common Stock
ECYT
$5.58M 0.45%
418,715
+349,909
+509% +$5.53M
AMRN
39
PUT
Amarin Corp
AMRN
$297M
$5.49M 0.45%
+43,425
New +$5.2M
VNDA icon
40
CALL
Vanda Pharmaceuticals
VNDA
$304M
$5.28M 0.43%
+482,600
New +$5.16M
RPRX
41
CALL
DELISTED
Repros Therapeutics Inc.
RPRX
$5.17M 0.42%
+193,000
New +$4.14M
ITMN
42
DELISTED
INTERMUNE INC
ITMN
$4.61M 0.37%
300,000
– –
IMMU
43
DELISTED
Immunomedics Inc
IMMU
$4.57M 0.37%
737,505
-1,639
-0.2% -$9.44K
STML
44
DELISTED
Stemline Therapeutics, Inc.
STML
$4.09M 0.33%
90,208
-501,442
-85% -$16.4M
ARRY
45
DELISTED
Array Biopharma Inc
ARRY
$3.56M 0.29%
572,870
+553,550
+2,865% +$3.29M
ATHX
46
DELISTED
Athersys, Inc. Common Stock
ATHX
$3.53M 0.29%
86,005
-53,163
-38% -$2.26M
FBIO icon
47
PUT
Fortress Biotech
FBIO
$111M
$3.52M 0.29%
+33,460
New +$4.1M
ANIK icon
48
Anika Therapeutics
ANIK
$215M
$3.44M 0.28%
+144,067
New +$3.23M
INFI
49
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$3.4M 0.28%
195,155
+83,215
+74% +$1.59M
NBIX icon
50
PUT
Neurocrine Biosciences
NBIX
$18.2B
$3.28M 0.27%
+289,500
New +$3.98M
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2013 Portfolio in Review

As of Q3 2013, Perceptive Advisors held 137 positions worth $1.23B, up 24% from $992M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Perceptive Advisors deployed $116M of net new capital in Q3 2013, opening 51 new positions and adding to 28 existing holdings. Its largest new stake was ONYX PHARMACEUTICALS INC: 556,944 shares worth $69.5M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 80% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Aegerion Pharmaceuticals, an estimated $106M trimmed.

  • Perceptive Advisors's largest Q3 2013 buy was ONYX PHARMACEUTICALS INC: 556,944 shares worth $69.5M.
  • Perceptive Advisors added most to Celgene Corp in Q3 2013, an estimated $37.6M increase.
  • Perceptive Advisors's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $106M.
  • Perceptive Advisors fully exited Biogen in Q3 2013, selling an estimated $49.8M.
  • Perceptive Advisors's ten largest holdings make up 61% of its $1.23B portfolio in Q3 2013.
  • Perceptive Advisors opened 51 new positions and closed 23 in Q3 2013.
  • Perceptive Advisors's portfolio value rose 24% quarter-over-quarter to $1.23B.

Based on Perceptive Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.